

## Scientific Committee on Emerging and Zoonotic Diseases

## Summary of Recommendations on Antiviral Stockpiling for Influenza Pandemics

Antivirals are available for treatment and prophylaxis against influenza infection and scientific evidence showed that some antivirals are effective against infection with influenza viruses. While there is no guarantee that existing antivirals would be effective against a novel influenza strain that emerges in the next pandemic, advance stockpiling of antivirals is justified to ensure their availability during a pandemic.

- 2. The two locally registered neuraminidase inhibitors, namely oseltamivir (Tamiflu) and zanamivir (Relenza), can be recommended in an antiviral stockpile. Oseltamivir, which is administered orally, can be given both for prophylaxis and treatment; while zanamivir, which is administered inhalationally, may be considered in treating patients without pre-existing airway diseases.
- 3. Based on review of the scientific literature and the practices of other developed countries, the Government is advised to continue to stockpile antivirals for both treatment and post-exposure prophylaxis purpose in anticipation of the next influenza pandemic.
- 4. Due to the unpredictability of any future pandemic strain, antiviral resistance of existing influenza strains with pandemic potential should be monitored. Besides, the progress of development and availability of other antivirals should be monitored closely.



衛生防護中心乃衛生署 轄下執行疾病預防 及控制的專業架構 The Centre for Health Protection is a professional arm of the Department of Health for disease prevention and control

## Centre for Health Protection October 2014

This statement represents a consensus view of members of the Scientific Committee reached in the light of scientific information accessible and examined at the time of its release.

The copyright of this paper belongs to the Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region. Contents of the paper may be freely quoted for educational, training and non-commercial uses provided that acknowledgement be made to the Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region. No part of this paper may be used, modified or reproduced for purposes other than those stated above without prior permission obtained from the Centre.



